These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35980440)

  • 1. Romosozumab successfully regulated progressive osteoporosis in a patient with autosomal dominant polycystic kidney disease undergoing hemodialysis.
    Suzuki T; Mizobuchi M; Yoshida S; Terado N; Aoki S; Sato N; Honda H
    Osteoporos Int; 2022 Dec; 33(12):2649-2652. PubMed ID: 35980440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positioning novel biologicals in CKD-mineral and bone disorders.
    Tartaglione L; Pasquali M; Rotondi S; Muci ML; Covic A; Mazzaferro S
    J Nephrol; 2017 Oct; 30(5):689-699. PubMed ID: 28540603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romosozumab for the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study.
    Sato M; Inaba M; Yamada S; Emoto M; Ohno Y; Tsujimoto Y
    J Bone Miner Metab; 2021 Nov; 39(6):1082-1090. PubMed ID: 34324082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.
    Hsu CY; Chen LR; Chen KH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romosozumab used to treat a patient with cystic fibrosis-related osteoporosis.
    Crow HM; Graves L; Anabtawi A
    Am J Med Sci; 2022 Oct; 364(4):461-465. PubMed ID: 35469767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romosozumab improves low bone mineral density in a postmenopausal woman undergoing chronic hemodialysis and treated with a calcium-sensing receptor agonist.
    Ogata M; Ushimaru S; Fujishima R; Sumi H; Shiizaki K; Tominaga N
    Bone Rep; 2022 Dec; 17():101639. PubMed ID: 36438716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates in CKD-Associated Osteoporosis.
    Khairallah P; Nickolas TL
    Curr Osteoporos Rep; 2018 Dec; 16(6):712-723. PubMed ID: 30353319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Romosozumab : a new treatment for severe osteoporosis].
    Uebelhart B; Ferrari S
    Rev Med Suisse; 2021 Apr; 17(735):784-787. PubMed ID: 33881241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it!
    Brandenburg VM; Verhulst A; Babler A; D'Haese PC; Evenepoel P; Kaesler N
    Nephrol Dial Transplant; 2019 Mar; 34(3):408-414. PubMed ID: 29846712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romosozumab: a novel bone anabolic treatment option for osteoporosis?
    Kerschan-Schindl K
    Wien Med Wochenschr; 2020 Apr; 170(5-6):124-131. PubMed ID: 31858345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study.
    Tominaga A; Wada K; Kato Y; Nishi H; Terayama Y; Okazaki K
    Osteoporos Int; 2021 Apr; 32(4):653-661. PubMed ID: 32979066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.
    Chavassieux P; Chapurlat R; Portero-Muzy N; Roux JP; Garcia P; Brown JP; Libanati C; Boyce RW; Wang A; Grauer A
    J Bone Miner Res; 2019 Sep; 34(9):1597-1608. PubMed ID: 31233639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: A case report.
    Uehara M; Nakamura Y; Nakano M; Miyazaki A; Suzuki T; Takahashi J
    Mod Rheumatol Case Rep; 2022 Jan; 6(1):128-133. PubMed ID: 34491363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease.
    Miyauchi A; Hamaya E; Nishi K; Tolman C; Shimauchi J
    J Bone Miner Metab; 2022 Jul; 40(4):677-687. PubMed ID: 35639174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Teriparatide:benefit and safety for bone disease in CKD patients undergoing hemodialysis].
    Yamamoto S; Ei I; Narita I
    Clin Calcium; 2016 Sep; 26(9):1301-7. PubMed ID: 27561345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphophonates in CKD patients with low bone mineral density.
    Liu WC; Yen JF; Lang CL; Yan MT; Lu KC
    ScientificWorldJournal; 2013; 2013():837573. PubMed ID: 24501586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Kato Y
    Osteoporos Int; 2021 Oct; 32(10):1999-2009. PubMed ID: 33770201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.